Pregnancy After Cardiac Surgery.
Review published in Cureus (2022)
Abstract
Women with native heart valve disease who are considering getting pregnant should have a complete risk estimation to determine whether an intervention is required prior to becoming pregnant and, if so, to determine when it should be performed and what kind of surgical therapy will be used. Pregnancy is linked to early and late structural valve degeneration in women who have bioprostheses, suggesting a high reoperation rate. A mechanical valve during pregnancy increases the risk of maternal complications such as valve thrombosis and mortality. The claim that women with defective hearts should not become pregnant was driven by the high maternal death rate among cardiac patients who became pregnant. A preoperative anticoagulation therapy trial helped women scheduled for valve replacement to acquire complete information as to the choice of the prosthetic device. Integrated risk stratification scheme for pregnant patients with valvular heart disease, with WHO classification and an algorithmic approach to both preconception counseling and anticoagulation strategy as outlined here, as well as early referral to a cardiologist with expertise in the management of cardiac disease and pregnancy for these complex patients is recommended. However, in reality, some women present while pregnant and valve disease needs to be managed, balancing maternal outcome and fetal risk. In general, optimizing the hemodynamic situation of the mother is also beneficial to the fetus. However, cardiac surgery carries a high risk for the fetus. No anticoagulant regimen can be said to be entirely safe for use during pregnancy, as there is a degree of risk with each regimen. Therefore, this review has been done to find appropriate management for women dealing with such conditions.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Women with native heart valve disease who are considering getting pregnant should have a complete risk estimation to determine whether an intervention is required prior to becoming pregnant and, if so, to determine when it should be performed and what kind of surgical therapy will be used....
Por qué esto importa para la hirudoterapia
Esta revisión examina el manejo del embarazo en mujeres con enfermedad valvular cardíaca nativa o protésica, centrándose en la estratificación del riesgo y las estrategias de anticoagulación durante el embarazo. Es relevante para el ámbito de ASH en la medida en que la anticoagulación es un tema central —se analizan los riesgos de trombosis valvular con válvulas mecánicas y se señala que ningún régimen anticoagulante es completamente seguro durante el embarazo. Sin embargo, el artículo no menciona sanguijuelas, hirudoterapia, hirudina ni ningún agente derivado de la sanguijuela. Su relevancia se limita al contexto más amplio de la anticoagulación que los profesionales de la hirudoterapia pueden encontrar de forma indirecta.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026